China
Africa
Explore chapters and articles related to this topic
Pulsed estrogen therapy may lead to lower breast stimulation than with daily continuous estrogen exposure
Published in A. R. Genazzani, Hormone Replacement Therapy and Cancer, 2020
N. Mabon, C. Varin, Y. Tsouderos
Mastodynia is a main cause of withdrawal1,2 from treatment, when in fact compliance is necessary in order to take advantage of the long-term benefits of estrogen replacement therapy, namely prevention of osteoporosis and cardiovascular and neurodegenerative diseases. Mastalgia is a hormone-dependent symptom and is often a sign of overdosing, especially when moderate or severe in intensity. Using marketed patches delivering the same estrogen doses (50 µg/day), similar incidences of mastodynia have been reported in two recently published results of clinical trials19,20, and also by Lopes and colleagues16 with the TTS 50 in a comparison with Aerodiol®. In this comparative study, a significantly lower incidence of moderate and severe mastodynia was observed with the pulsed estrogen therapy (7.2% vs. 15.5%, p = 0.02).
Breast
Published in Keith Hopcroft, Vincent Forte, Symptom Sorter, 2020
Breast pain have a variety of innocent causes: the commonest are puberty and pregnancy. It can be a troublesome recurrent problem for women with cyclical mastalgia. Cancer is very likely to be a major concern: this is an uncommon cause and pain is an unfortunately late sign of the disease.
Breast disorders in children and adolescents
Published in Joseph S. Sanfilippo, Eduardo Lara-Torre, Veronica Gomez-Lobo, Sanfilippo's Textbook of Pediatric and Adolescent GynecologySecond Edition, 2019
Nirupama K. De Silva, Monica Henning
Fibrocystic changes in the breast can result in both localized masses and pain in the breast (also termed mastalgia). Patients should be reassured that this is a normal variant of female physiology with these changes reported in 50% of women of reproductive age and 90% of women on autopsy.20 These patients tend to present with pain before menses and have relief after menses.1 Physical examination alone usually suffices to make this diagnosis, since in most patients there is significant change with serial examinations done at different points in the menstrual cycle. Ultrasound may be helpful if the diagnosis is equivocal, but mammography is not indicated. The treatment of mastalgia includes a properly fitted and firm brassiere and nonsteroidal anti-inflammatory drugs (NSAIDS). Oral contraceptives have been reported to improve symptoms in 70%–90% of women.20 Treatments with vitamin E and evening primrose oil and avoidance of caffeine are unproven but popular.20
Effectiveness of Matricaria chamomilla (chamomile) extract on pain control of cyclic mastalgia: a double-blind randomised controlled trial
Published in Journal of Obstetrics and Gynaecology, 2018
N. Saghafi, H. Rhkhshandeh, N. Pourmoghadam, L. Pourali, M. Ghazanfarpour, A. Behrooznia, F. Vafisani
Prior to the intervention, two groups were clinically similar in terms of the severity of mastalgia symptoms that most participants had moderate degree of mastalgia. Thirty women received chamomile and the remaining 30 subjects received placebo. The chamomile group was asked to take five drops three times a day; in the morning, midday, and at night – each time having five drops with a glass of warm water for two consecutive months. The substances used in the chamomile extract (Chamomile produced by Zardband Pharmaceutical, Tehran, Iran) and placebo drops (distilled water) had similar external properties. At each follow-up visit (at the end of first and second month of starting the study), the intake of treatment/placebo by each woman and the side effects (allergic reactions, nausea, vomiting, headache) were checked. Also, a telephone follow-up was performed 2, 4, 6 and 8 weeks after the onset of the intervention.
Noncyclical and cyclical mastalgia in Turkish women: Prevalence, risk factors, health-care seeking and quality of life
Published in Health Care for Women International, 2022
Hacı Bolat, Özlem Aşcı, Servet Kocaöz, Semra Kocaöz
Mastalgia of unknown etiology is reported to be the most common breast symptom in women (Jokich et al., 2017). The prevalence is reported as 16-59% in studies conducted in different populations (alJbeery et al., 2017; Johnson et al., 2006; Koçoğlu et al., 2017; Makumbi et al., 2014; Mohammed, 2020; Scurr et al., 2014; Vaziri et al., 2016). We found that mastalgia was seen in approximately one out of five women (20.7%) in this study conducted in general surgery outpatient departments. This figure was close to the lower limit of the results from other studies as mentioned above. The different results could be due to the population studied, the place where the study was conducted, and the diagnostic criteria used to define the mastalgia.